Evoq Remedies Ltd
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE %
- ROE %
- Face Value ₹
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Services Services Commercial Services & Supplies Trading & Distributors
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Dividend Payout % |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Equity Capital |
| Reserves |
| Total Liabilities |
| CWIP |
| Investments |
| Total Assets |
Cash Flows
Figures in Rs. Crores
| Net Cash Flow |
| Free Cash Flow |
| CFO/OP |
Ratios
Figures in Rs. Crores
| Debtor Days |
| Inventory Days |
| Days Payable |
| Cash Conversion Cycle |
| Working Capital Days |
| ROCE % |
Insights
In beta| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Advance from Customers Rs. Lakhs ・Standalone data |
|
||||
| Inventory (Stock-in-Hand) Rs. Lakhs ・Standalone data |
|||||
| Purchases of Stock-in-Trade Rs. Lakhs ・Standalone data |
|||||
| Sales Commission Income Rs. Lakhs ・Standalone data |
|||||
| Trade Receivables Rs. Lakhs ・Standalone data |
|||||
| Export Order Secured Rs. Crores ・Standalone data |
|||||
Extracted by Screener AI
Documents
Announcements
-
Board Meeting Intimation for Intimation For Rescheduling Of Board Meeting From 14Th May, 2026 To 27Th May, 2026
11 May - Board meeting rescheduled from 14 May 2026 to 27 May 2026 to consider audited FY2026 results.
-
Board Meeting Intimation for Intimation Of Board Meeting To Be Held On Thursday, 14Th May, 2026
7 May - Board meeting on 14 May 2026 to approve audited half-year and year-end results for 31 March 2026.
-
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
30 Apr - Evoq Remedies confirms it is not a Large Corporate; outstanding borrowing nil as of 31 March 2026.
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 9 Apr
-
Closure of Trading Window
30 Mar - Trading window closed from 1 April 2026 until 48 hours after audited results for half-year/year ended 31 March 2026.
Business Overview:[1]
EVOQRL deals in the trading of the pharma
products and commission agent in pharma products, etc.